Compare UUU & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUU | QNRX |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 9.2M |
| IPO Year | 2025 | 2023 |
| Metric | UUU | QNRX |
|---|---|---|
| Price | $3.50 | $4.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.4K | ★ 13.6K |
| Earning Date | 02-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,847,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $3.25 |
| 52 Week High | $8.27 | $41.80 |
| Indicator | UUU | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 54.86 |
| Support Level | $3.02 | $4.55 |
| Resistance Level | $4.13 | $5.11 |
| Average True Range (ATR) | 0.30 | 0.23 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 50.25 | 81.69 |
Universal Safety Products Inc designs and markets a variety of popularly priced safety products which, consisted mainly of smoke alarms, carbon monoxide alarms and related products. Its products require minimal installation and are designed for easy installation by the consumer without professional assistance and are sold through retail stores. It also market products to the electrical distribution trade. The electrical distribution trade includes electrical and lighting distributors as well as manufactured housing companies. Products it sell usually require professional installation. Its products are 2-in-1 Smoke & Fire Alarms, 3-in-1 Combo Alarms, and CO Alarms.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.